- Home
- PRIM vs AKRO Comparison
PRIM vs AKRO Comparison
Compare PRIM & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRIM
- AKRO
- Stock Information
- Founded
- PRIM 1960
- AKRO 2017
- Country
- PRIM United States
- AKRO United States
- Employees
- PRIM N/A
- AKRO N/A
- Industry
- PRIM Water Sewer Pipeline Comm & Power Line Construction
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- PRIM Industrials
- AKRO Health Care
- Exchange
- PRIM Nasdaq
- AKRO Nasdaq
- Market Cap
- PRIM 3.3B
- AKRO 2.8B
- IPO Year
- PRIM N/A
- AKRO 2019
- Fundamental
- Price
- PRIM $68.30
- AKRO $39.85
- Analyst Decision
- PRIM Strong Buy
- AKRO Strong Buy
- Analyst Count
- PRIM 8
- AKRO 9
- Target Price
- PRIM $85.75
- AKRO $76.29
- AVG Volume (30 Days)
- PRIM 910.3K
- AKRO 1.1M
- Earning Date
- PRIM 05-05-2025
- AKRO 05-16-2025
- Dividend Yield
- PRIM 0.47%
- AKRO N/A
- EPS Growth
- PRIM 41.89
- AKRO N/A
- EPS
- PRIM 3.77
- AKRO N/A
- Revenue
- PRIM $6,602,243,000.00
- AKRO N/A
- Revenue This Year
- PRIM $7.07
- AKRO N/A
- Revenue Next Year
- PRIM $5.35
- AKRO N/A
- P/E Ratio
- PRIM $18.13
- AKRO N/A
- Revenue Growth
- PRIM 12.45
- AKRO N/A
- 52 Week Low
- PRIM $45.92
- AKRO $17.86
- 52 Week High
- PRIM $90.86
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- PRIM 64.84
- AKRO 44.56
- Support Level
- PRIM $63.36
- AKRO $41.60
- Resistance Level
- PRIM $70.29
- AKRO $46.47
- Average True Range (ATR)
- PRIM 2.29
- AKRO 2.26
- MACD
- PRIM 1.21
- AKRO 0.08
- Stochastic Oscillator
- PRIM 87.55
- AKRO 21.84
About PRIM Primoris Services Corporation
Primoris Services Corp is a provider of infrastructure services operating mainly in the United States and Canada. It provides a wide range of construction services, maintenance, replacement, fabrication and engineering services to a diversified base of customers. The reportable segments are the Utilities segment and the Energy segment. The Utilities segment operates in a range of services, including the installation and maintenance of new and existing natural gas and electric utility distribution and transmission systems, and communication systems. The Energy segment operates in a range of services that include engineering, procurement, and construction, retrofits, highway and bridge construction, demolition, site work, outages, pipeline construction and maintenance, and others.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.